What is PSTV's current stock price?

PSTV (Plus Therapeutics, Inc.) is currently trading at $6.81 with a market cap of $16.5M.

What sector is Plus Therapeutics, Inc. in?

Plus Therapeutics, Inc. (PSTV) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PSTV a good stock to buy?

Analysts have a Buy consensus on PSTV with a price target of $25.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PSTV Plus Therapeutics, Inc.

Healthcare

$6.81+0.00%OpenMarket Cap: $16.5M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.66

P/S

3.08

EV/EBITDA

-1.62

DCF Value

$-0.88

FCF Yield

-136.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

92.8%

Operating Margin

-364.4%

Net Margin

-230.2%

ROE

-198.5%

ROA

-59.9%

ROIC

-148.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$1.0M	$-6.9M	$—
Q4 null	$1.4M	$-5.7M	$—
FY null	$5.2M	$-22.4M	$—
Q3 null	$1.4M	$-4.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$25.00

Target (Median)

$25.00

Target Range

$25.00 - $25.00

1 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

Ascendiant CapitalBuy

2026-04-09

D. Boral CapitalHold

2026-03-31

D. Boral CapitalBuy

2026-03-19

HC Wainwright & Co.Buy

2026-01-23

D. Boral CapitalBuy

2026-01-22

Trading Activity

Insider Trades

View All

van Es-Johansson Andirector

SellMon May 18

Hawkins Richard Jdirector

SellMon May 18

Guse Kyledirector

SellMon May 18

Clowes Howarddirector

SellMon May 18

ANDREWS RONALD ASBURYdirector

SellMon May 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.40

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Peers